820P Leronlimab (LRM) in combination with trifluridine/tipiracil (TAS-102) plus bevacizumab (BEV) in metastatic colorectal cancer (mCRC): The phase 2 CLOVER study
Annals of Oncology · 2026-12 · 37 · S697-S698
DOI: 10.1016/j.annonc.2026.08.1007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Oncology, 2026-12. Verfasst von B. Weinberg und 14 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Weinberg, B., Baron, A., Chaudhry, A., Tenner, L., Vijayvergia, N., Driscoll, M., Noel, M., Rui, H., Adams, D., Duffy, A., Pestell, R., Vittner, P., Meidling, J., Lalezari, J., & Kasi, P. (2026). 820P Leronlimab (LRM) in combination with trifluridine/tipiracil (TAS-102) plus bevacizumab (BEV) in metastatic colorectal cancer (mCRC): The phase 2 CLOVER study. Annals of Oncology, 37, S697-S698. https://doi.org/10.1016/j.annonc.2026.08.1007
Vancouver
Weinberg B, Baron A, Chaudhry A, Tenner L, Vijayvergia N, Driscoll M, et al. 820P Leronlimab (LRM) in combination with trifluridine/tipiracil (TAS-102) plus bevacizumab (BEV) in metastatic colorectal cancer (mCRC): The phase 2 CLOVER study. Annals of Oncology. 2026;37:S697-S698. doi:10.1016/j.annonc.2026.08.1007
BibTeX
@article{Weinberg2026,
author = {Weinberg, B. and Baron, A. and Chaudhry, A. and Tenner, L.L. and Vijayvergia, N. and Driscoll, M.F. and Noel, M.S. and Rui, H. and Adams, D.L. and Duffy, A.B. and Pestell, R.G. and Vittner, P. and Meidling, J. and Lalezari, J.P. and Kasi, P.M.},
title = {820P Leronlimab (LRM) in combination with trifluridine/tipiracil (TAS-102) plus bevacizumab (BEV) in metastatic colorectal cancer (mCRC): The phase 2 CLOVER study},
journal = {Annals of Oncology},
year = {2026},
volume = {37},
pages = {S697--S698},
doi = {10.1016/j.annonc.2026.08.1007}
}
EUVIMED